ReviewWorld journal of hepatology2015
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Herb induced liver injury after using herbal medicine: A systemic review and case-control study.Medicine · 2019Pooled it
- Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS).BMC pharmacology & toxicology · 2024Article
- The effects of hepatic ischemia/reperfusion injury on postoperative cognitive function in aged rats.Archives of medical science : AMS · 2022Article
- Drug Induced Liver Injury: Perspective of the Adverse Drug Reaction Reports to the Portuguese Pharmacovigilance System from 2010 to 2019.Healthcare (Basel, Switzerland) · 2021Article
- Antidepressants- and antipsychotics-induced hepatotoxicity.Archives of toxicology · 2021Review
- Aqueous Partition of Methanolic Extract ofNutrients · 2019Article
- Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration.Acta pharmaceutica Sinica. B · 2019Article
- Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.Frontiers in pharmacology · 2019Review
- Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury.Archives of toxicology · 2018Article
- Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.Journal of food and drug analysis · 2018Review
- The hepatoprotective role of reduced glutathione and its underlying mechanism in oxaliplatin-induced acute liver injury.Oncology letters · 2018Article
- Article
- Article
- Drug-induced liver injury: Do we know everything?World journal of hepatology · 2017Review
- Drug-induced liver injury: Towards early prediction and risk stratification.World journal of hepatology · 2017Review
- Review
- Iberogast-Induced Severe Hepatotoxicity Leading to Liver Transplantation.The American journal of gastroenterology · 2016Article
- Drug-induced liver injury associated with Complementary and Alternative Medicine: a review of adverse event reports in an Asian community from 2009 to 2014.BMC complementary and alternative medicine · 2016Article
- Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) and herb-induced liver injury is a hot topic for clinicians, academia, drug companies and regulators, as shown by the steadily increasing number of publications in the past 15 years. This review will first provide clues for clinicians to suspect idiosyncratic (unpredictable) DILI and succeed in diagnosis. Causality assessment remains challenging and requires careful medical history as well as awareness of multifaceted aspects, especially for herbs. Drug discontinuation and therapy reconciliation remain the mainstay in patent's management to minimize occurrence of acute liver failure. The second section will address novel agents associated with liver injury in 2014 (referred to as "signals"), especially in terms of clinical, research and drug development implications. Insights will be provided into recent trends by highlighting the contribution of different post-marketing data, especially registries and spontaneous reporting systems. This literature scrutiny suggests: (1) the importance of post-marketing databases as tools of clinical evidence to detect signals of DILI risk; and (2) the need for joining efforts in improving predictivity of pre-clinical assays, continuing post-marketing surveillance and design ad hoc post-authorization safety studies. In this context, ongoing European/United States research consortia and novel pharmaco-epidemiological tools (e.g., specialist prescription event monitoring) will support innovation in this field. Direct oral anticoagulants and herbal/dietary supplements appear as key research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.